Cho Sung-Yeon, Lee Hyeon-Jeong, Lee Dong-Gun
Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
The Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Korean J Intern Med. 2018 Mar;33(2):256-276. doi: 10.3904/kjim.2018.036. Epub 2018 Feb 27.
Hematopoietic stem cell transplantation (HSCT) is a treatment for hematologic malignancies, immune deficiencies, or genetic diseases, ect. Recently, the number of HSCTs performed in Korea has increased and the outcomes have improved. However, infectious complications account for most of the morbidity and mortality after HSCT. Post-HSCT infectious complications are usually classified according to the time after HSCT: pre-engraftment, immediate post-engraftment, and late post-engraftment period. In addition, the types and risk factors of infectious complications differ according to the stem cell source, donor type, conditioning intensity, region, prophylaxis strategy, and comorbidities, such as graft-versushost disease and invasive fungal infection. In this review, we summarize infectious complications after HSCT, focusing on the Korean perspectives.
造血干细胞移植（HSCT）是一种用于治疗血液系统恶性肿瘤、免疫缺陷或遗传性疾病等的方法。最近，韩国进行的HSCT数量有所增加，且治疗效果有所改善。然而，感染性并发症是HSCT后发病和死亡的主要原因。HSCT后的感染性并发症通常根据HSCT后的时间进行分类：植入前、植入后即刻和植入后晚期。此外,感染性并发症的类型和危险因素因干细胞来源、供体类型、预处理强度、地区、预防策略以及诸如移植物抗宿主病和侵袭性真菌感染等合并症的不同而有所差异。在本综述中，我们将从韩国的视角总结HSCT后的感染性并发症。
